MRNA raises price target to $120 from $67 after Phase 3 data
MRNA’s MRK-partnered intismeran autogene plus Keytruda therapy price target is lifted to $120 from $67 following a reported positive late-stage Ph3 result in completely resected Stage IIB-IV melanoma.